Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction

Author:

Smith Kimberly W.1,White C. Michael1ORCID

Affiliation:

1. Department of Pharmacy Practice University of Connecticut School of Pharmacy Storrs Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy SM;Circulation,2019

2. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia

3. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

4. Management of Statin Intolerance in 2018: Still More Questions Than Answers

5. Novartis Pharmaceuticals.Inclisiran package insert.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf. Published 2021. Accessed January 11 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3